Loading...
Market
Which pharmaceutical company will benefit most from China's drug price negotiations by end of 2025?
2
Resolution / Starting Odds
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Market reports and financial performance data of pharmaceutical companies
Story
China Cuts Drug Prices by 63%, Adding 91 New Drugs to Insurance List, Benefiting 830 Million People
Nov 28, 2024, 07:30 AM
China's National Healthcare Security Administration announced a significant update to its national medical insurance drug list, which now includes 91 new drugs. These drugs will see an average price reduction of 63%, leading to an estimated decrease in patient costs of over 50 billion yuan (approximately $6.95 billion) in 2025. The administration reported that, as of October 2024, medication price negotiations have benefited 830 million people and reduced the cumulative financial burden on patients by CNY 880 billion (around $121.5 billion) over the past seven years. This initiative is part of China's broader efforts to expand drug coverage and improve healthcare affordability for its citizens.
View original story
Similar markets
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck & Co. • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Novo Nordisk • 34%
Eli Lilly • 33%
Other • 33%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Donanemab leads • 25%
Leqembi leads • 25%
Both have equal share • 25%
Other treatments lead • 25%
Pfizer • 33%
Johnson & Johnson • 33%
Eli Lilly • 33%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%